Compare Annaly Capital Management, Inc. (NLY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Annaly Capital Management, Inc. trades at $18.31 (market cap $13.69B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Annaly Capital Management, Inc. is far larger — about 2.8× Travere Therapeutics Inc. Common Stock's market cap, and Annaly Capital Management, Inc. pays a 16.52% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NLY | TVTX | |
|---|---|---|
Market Cap | $13.69B | $4.88B |
Volume | 11,361,415 | 1,668,577 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $67.52 |
52-Week Low | $17.93 | $26.79 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $135.72B | $5.01B |
Dividend Yield | 16.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $18.16, down 0.71% on the day, as the mortgage REIT faces technical headwinds despite strong fundamentals. The stock exhibits a bearish technical signal with key resistance at $19, while recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.79 surpassing the $0.751 consensus. NLY maintains a high dividend yield, recently declaring a $0.75 quarterly payout, supported by a 92.77% net income margin and 20.66% ROE. The company's portfolio expansion to $107 billion in 2026 drives earnings growth, though rising interest rates pose challenges.
NLY presents a value opportunity with a P/E of 4.39 and P/B of 0.91, trading below the analyst consensus price target of $22.00. The 57% buy rating from analysts reflects confidence in its dividend sustainability and portfolio strength. Key risks include sensitivity to interest rate hikes, leveraged balance sheet with debt-to-asset ratio of 23.55 in 2025, and potential volatility in mortgage spreads. Investors are compensated with a high yield, but must monitor Federal Reserve policy impacts on mortgage REIT profitability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
